BioPharma Dive May 23, 2024
After laying off staff late last year, Orna is now expanding through the purchase of ReNAgade Therapeutics, which was built around technology designed to more effectively deliver RNA-based medicines.
Orna Therapeutics, a young biotechnology company focused on a flashy area of genetic research, is expanding through the acquisition of another well-funded startup.
As its name suggests, the startup, ReNAgade Therapeutics, was built around technology designed to more effectively deliver RNA-based medicines to specific parts of the body. ReNAgade launched a year ago, with $300 million in funding and an industry veteran, Amit Munshi, at its helm. The company had also created a joint venture to apply its technology to Orna’s “circular RNA” research.
Now, Orna is absorbing ReNAgade and making...
Today's Sponsors
Today's Sponsor